THANK YOU FOR SUBSCRIBING
Pharma firms that tap into the benefits of automating the gathering, processing, and reporting of adverse event data will soon leave their competitors behind when it comes to efficiency.
FREMONT, CA: Adverse event information comes from healthcare professionals, manufacturers, and patients themselves, creating huge data volumes to analyze. Life sciences organizations face a daily challenge gathering this pharmacovigilance data, evaluating its significance, and reporting it to the authorities in a rapid method to update safety data. If appropriate, additional measures can be taken. Pharma firms should be using the latest technology to gather and process this workload. The range of technology is considerable and has proven reliable and highly cost-efficient. However, firms could be exploiting these technologies more.
According to a recent survey, many pharma firms believe they are making fair use of technology for data capture and reporting. The research evaluates life sciences companies’ attitudes towards and plans for pharmacovigilance automation, especially for case intake and reporting. Many companies have already made substantial use of advanced technology in pharmacovigilance or are about to embrace advanced pharmacovigilance-associated technology. Digging deeper into these findings, organizations were already using automated case intake solutions or planned to do so over the year ahead.
Across all company sizes, firms considered the top three benefits of pharmacovigilance automation: improved compliance, higher reporting volumes, and speed. Of course, firms that can capture reliable information efficiently and effectively can process higher volumes of data, increasing the chance of identified and analyzed essential cases. Pharmacovigilance automation is occurring, but it is not reaching its full ability. This may be because pharmacovigilance functions are extensively viewed as a costly expense rather than processes that could add value. Only some companies are feeling that their organization would be significantly disadvantaged y a lack of pharmacovigilance automation.
The advantages of automating and improving pharmacovigilance data are not high on the priority list of senior stakeholders. However, firms that tap into the very tangible benefits of automating the gathering, processing, and reporting of adverse event data will soon leave rivals standing when it comes to efficiency.